Form 4: Ligand Pharmaceuticals Insider Trades Common Stock

Andrew Reardon, CLO & Secretary of Ligand Pharmaceuticals Inc., reported transactions involving the acquisition of stock options and the sale of common stock on April 1, 2026, under a Rule 10b5-1 trading plan.

Summary

• Andrew Reardon, Chief Legal Officer and Secretary of Ligand Pharmaceuticals Inc., executed several transactions on April 1, 2026.
• He acquired 5,000 employee stock options with an exercise price of $52.27.
• Concurrently, he sold a total of 4,237 shares of common stock in multiple transactions at weighted-average prices ranging from $198.40 to $204.82.
• These sales were conducted under a pre-established trading plan adopted on November 24, 2025, in compliance with Rule 10b5-1(c) to satisfy affirmative defense conditions.
• Following these transactions, Reardon beneficially owns 41,382 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the execution under a pre-arranged 10b5-1 plan mitigates concerns about adverse market timing or lack of confidence.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• Acquisition of 5,000 employee stock options suggests continued alignment with company performance and long-term incentives.

Negatives

• A significant number of shares (4,237) were sold by a key executive, which could be perceived negatively by the market, despite being part of a pre-planned strategy.

Risks

• While the sales were made under a 10b5-1 plan, significant insider selling can sometimes be interpreted as a lack of confidence in future stock performance.
• The weighted-average sale prices indicate a range of market values at which the shares were disposed of.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports past transactions.

Management Comments

• The transactions reported on this Form 4 were made pursuant to a written trading plan adopted by the Reporting Person on November 24, 2025, in accordance with Rule 10b5-1.
• The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event for executives managing their personal finances and diversifying holdings. However, the volume and timing relative to other market events can influence investor perception within the biopharmaceutical sector, which is often sensitive to executive sentiment.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by a key executive with mixed sentiment, though the 10b5-1 plan provides a mitigating factor.
• Employees: The acquisition of stock options by management can be seen as a positive sign of continued commitment and belief in the company's future.
• Creditors: No direct impact is indicated by this filing.

Key Dates

Keywords

Form 4, Insider Trading, Ligand Pharmaceuticals, LGND, Stock Options, Common Stock, Rule 10b5-1, Andrew Reardon, CLO, Secretary, Beneficial Ownership